Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xbiotech Inc (NQ: XBIT )

7.500 +0.100 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,363
Open 7.340
Bid (Size) 4.000 (61)
Ask (Size) 8.500 (5)
Prev. Close 7.400
Today's Range 7.325 - 7.600
52wk Range 3.510 - 9.960
Shares Outstanding 30,436,964
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
XBiotech just reported results for the second quarter of 2024. 
Via InvestorPlace
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin... 
Via Benzinga

Performance

YTD
+72.81%
+72.81%
1 Month
+30.43%
+30.43%
3 Month
+31.81%
+31.81%
6 Month
-11.45%
-11.45%
1 Year
+94.81%
+94.81%

More News

Read More
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024
Via InvestorPlace
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
From XBiotech Inc.
Via GlobeNewswire
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
From XBiotech Inc.
Via GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
From XBiotech Inc.
Via GlobeNewswire
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Dow Jumps Over 100 Points; US Housing Starts Rise In April
Via Benzinga
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
From XBiotech Inc.
Via GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
From XBiotech Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
From XBiotech Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.